Western University

Scholarship@Western
Neuroscience Institute Publications

Western Institute for Neuroscience

8-10-2022

Understanding the Association of Childhood Tobacco Use with
Neuropathological Outcomes and Cognitive Performance Deficits
in Vulnerable Brains
Steven R. Laviolette
Schulich School of Medicine & Dentistry, slaviole@uwo.ca

Follow this and additional works at: https://ir.lib.uwo.ca/neurosci_inst_pubs

Citation of this paper:
Laviolette, Steven R., "Understanding the Association of Childhood Tobacco Use with Neuropathological
Outcomes and Cognitive Performance Deficits in Vulnerable Brains" (2022). Neuroscience Institute
Publications. 133.
https://ir.lib.uwo.ca/neurosci_inst_pubs/133

Invited Commentary | Substance Use and Addiction

Understanding the Association of Childhood Tobacco Use With Neuropathological
Outcomes and Cognitive Performance Deficits in Vulnerable Brains
Steven R. Laviolette, PhD

Despite considerable progress in reducing overall rates of tobacco use during the past few decades,
we are currently experiencing dramatic increases in the rates of pediatric and adolescent
consumption of nicotine-containing products. These highly concerning trends correspond to the
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rising popularity of vaping and electronic cigarette (e-cigarette) technologies, a phenomenon that
represents a new smoking epidemic among young people. Indeed, despite some jurisdictional
attempts to limit youth access to these products, many of these nicotine-delivery devices are now
marketed specifically to young people, with the growing popularity of flavored e-cigarette and
vaping offerings combined with youth-oriented marketing campaigns.1 In addition to these market
factors, the increasing prevalence of mood and anxiety disorders related to the ongoing impacts of
the COVID-19 pandemic has led to a corresponding increase in vaping and e-cigarette consumption,
particularly among young people.
Neurodevelopment during the prepubescent and adolescent years involves intricate synaptic
pruning and neural reorganization mechanisms concomitant with the maturation of complex neural
circuits, cortical and subcortical connectivity patterning, and fine-tuning of critical neural networks
essential for healthy cognitive function and emotional regulation.2 These temporally orchestrated
neurodevelopmental events take place in the context of increased risk-taking behaviors and the
greater likelihood of drug experimentation, typical of childhood and adolescence. This confluence of
neurodevelopmental and behavioral dispositions renders the developing brain exquisitely sensitive
to extrinsic chemical insults, particularly in the form of dependence-producing drugs, including
nicotine, the primary psychoactive compound in tobacco products. Indeed, the brain’s cholinergic
system, which is critically involved in many neurotrophic processes during normal brain maturation,
is particularly vulnerable during these neurodevelopmental windows and is the primary target of
nicotine. Nicotine acts directly on nicotinic acetylcholine receptors found ubiquitously in the brain,
including cortical and subcortical circuits essential for normal cognitive and emotional regulation.3
Extrinsic nicotine exposure may therefore disrupt acetylcholine’s temporal regulation of various
trophic cellular events required for healthy brain development. However, beyond the cholinergic
system, neurodevelopmental nicotine exposure has been shown to act as a potent neurotoxin
affecting various neural systems. For example, in preclinical animal models, adolescent nicotine
exposure has been reported to cause long-term dysregulation of cortical and subcortical affective
and cognitive neural networks involving dopamine and glutamate signaling, as well as disruption of
molecular signaling pathways associated with cognitive disturbances and mood and anxiety
disorders.4,5
Dai and colleagues6 present compelling and novel clinical data demonstrating some significant
and deleterious associations of childhood smoking behaviors and nicotine exposure with
neurodevelopmental trajectories and cognitive performance measures. Using an integrative
combination of cognitive testing measures, morphometric assays, and structural magnetic resonance
imaging, the authors found that exposure to e-cigarettes and/or other tobacco products among a
cohort of children aged 9 to 10 years selected from a socioeconomically and ethnographically diverse
sample from the US displayed significant and enduring cognitive impairments. Using a battery of
cognitive assays, the authors reported significant performance deficits in children exposed to
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nicotine products, including measures of oral reading recognition, pattern comparison processing
speed, and picture vocabulary tests.
In terms of neuropathological outcomes, using structural magnetic resonance imaging and
morphometric analyses, Dai and colleagues6 found that several whole-brain measures were
significantly lower among participants exposed to tobacco during childhood, including reductions in
total cortical area and volume along with significant reductions in cerebral white matter volume. In
addition, the authors found additional structural associations, including lower cortical surface areas
in the superior frontal, medial orbitofrontal, paracentral, inferior parietal, middle temporal, superior
temporal sulcus, and several other neural regions. These neural regions are well-defined for their
critical roles in cognition, emotional regulation, and affective processing. Importantly, many of these
observed neuropathological outcomes were present 2 years after the initial analyses were
performed, suggesting potential long-term associations with even limited childhood nicotine
exposures. Such findings are consistent with those of preclinical studies showing that even limited
exposure to nicotine during periods of adolescent brain development can lead to long-term deficits in
cognition and dysregulation of frontal cortical function.4,5
The risks of childhood nicotine exposure for long-term cognitive outcomes extend beyond selfadministration. Indeed, previous evidence has shown that exposure to parental smoking is similarly
associated with poorer cognitive outcomes in later life. For example, Rovio et al7 reported that
childhood exposure to parental second-hand smoke was associated with significantly increased risk
for deficits in midlife episodic memory function and associative learning, along with impairments in
short-term and spatial working memory. In addition, a growing body of research using both clinical
and translational animal models are reporting that prenatal nicotine exposure may similarly lead to
long-term neuropsychiatric disorders in offspring. Finally, it is well-established that nicotine
dependence is highly comorbid with a wide range of neuropsychiatric disorders, including mood and
anxiety disorders, schizophrenia, and other substance use disorders such as alcohol and cannabis
use, although the mechanistic associations between these comorbidities are poorly understood.
Together, this emerging evidence from both preclinical and clinical studies underscores the
neurotoxic effects of nicotine exposure during sensitive periods of brain development and highlights
the ability of nicotine to pathologically interfere with a host of neurochemical, morphological, and
molecular pathways critical to healthy cognitive outcomes and long-term mental health.
The findings reported by Dai and colleagues6 raise many important questions for future clinical
and preclinical investigations. Notably, it will be important to determine how persistent these
pathophysiological outcomes remain beyond the windows of prepubertal and adolescent brain
maturation. In addition, it will be critical to identify the specific molecular mechanisms and
biomarkers underlying these enduring, tobacco-induced pathophysiological outcomes.
Characterizing these underlying mechanisms can potentially lead to the identification of more
effective intervention and/or reversal strategies for ameliorating neuropsychiatric phenotypes
caused by pediatric, adolescent, and perhaps even prenatal nicotine exposure. In addition, advances
in genomic and transcriptomic assays may provide improved understanding of the underlying
genetic factors that may predispose individuals to a greater risk of accessing nicotine products during
critical periods of brain development and of the factors that may render certain individuals at
increased risk of severe neuropathological and neurocognitive outcomes after exposure to nicotine
during the developmental windows. Finally, given that the observed structural abnormalities
reported in this study are critical biomarkers for a host of neuropsychiatric disorders, including
schizophrenia, mood and anxiety disorders, and drug dependence, it will be critical to determine
precisely how these nicotine-related neurodevelopmental perturbations might increase risk for
future neuropsychiatric disorders and/or psychiatric comorbidities with nicotine dependence.
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